Effects of thymoquinone in a rat model of reserpine-induced depression

Kuzay, Dilek; Dileköz, Ergin; Özer, Çiğdem

doi:10.1590/s2175-97902022e19847

Cited by 4 publications

(6 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effect on body weight loss is well established and can serve as a predictor of the degree of "reserpinization" (Halaris and Freedman, 1975). Along with the current study, chronic reserpine administration under different administration schemes have reported induced body weight loss in rats (Kuzay et al, 2022;Sethy and Hodges Jr., 1985). However, contradictory outcomes have also been shown (Ikram and Haleem, 2017).…”

Section: Reserpine Effects On Physiology and Well-beingsupporting

confidence: 59%

Reserpine-induced rat model of depression: behavioral, physiological and dopamine receptor PET based validation

Telega,

Berti,

Blazhenets

et al. 2023

Preprint

View full text Add to dashboard Cite

Background. Reserpine, a monoamine depleting agent, has been used in preclinical research for many years to create animal models of depression and to test experimental antidepressant strategies. Nevertheless, evidence of the potential use and validity of reserpine as a chronic pharmacological model for depression is lacking, and there are no comprehensive studies of the behavioral effects in conjunction with molecular outcomes. Results. Experiment 1. Following baseline behavior testing sensitive to depressive-like phenotype and locomotion (Phase 1), 27 Sprague-Dawley (SD) rats received i.p. either vehicle solution (0.0 mg/kg), low (0.2 mg/kg) or high (0.8 mg/kg) resrpine dose for 20 days using a pre-determined schedule and reassessed for emerging behavioral phenotypes (Phase 2). After a 10 days washout period, a final behavioral assessment was done (Phase 3), and the brains were collected for gene-expression assessment. Experiment 2. In a similar timetable as in Experiment 1 but without the behavioral testing, 12 SD rats underwent repetitive dopamine D2 receptor (D2R) PET scanning with [18F]DMFP post Phases 1–3. The binding potential (BPND) of [18F]DMFP was quantified by kinetic analysis as a marker of striatal D2R availability. Weight and welfare were monitored throughout the experiment. Significant, dose-dependent weight loss and behavioral deficits including both motor (hypo-locomotion) and non-motor behavior (anhedonia, mild anxiety and reduced socialization) were found for both the low and high dose groups with significant decrease in D2R mRNA expression in the accumbal region for the low reserpine group. In addition, both drug treated groups showed a substantial increase in [18F]DMFP BPND (in line with dopamine depletion) during injection phase and washout phases compared to baseline and Controls. Conclusions. The longitudinal design of the study demonstrated that chronic RES administration induced anxiety and depressive symptoms that were moderately maintained even after the wash out period. The data suggests that the low dose RES administration can induce a rodent model of depression with good face validity.

show abstract

Section: Reserpine Effects On Physiology and Well-beingsupporting

confidence: 59%

Reserpine-induced rat model of depression: behavioral, physiological and dopamine receptor PET based validation

Telega,

Berti,

Blazhenets

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…While FST is understood to evaluate behavioral despair, which may be related to concepts of learned helplessness [71], these should not be considered unconditionally when employed as a lone measure of affective function. Additional data for depression-like behaviors were identified with the Tail Suspension Test (TST) paradigm [49,51,58,66], although results failing to find these effects were also highlighted [72]. Results from Sucrose Preference Test (SPT) and Novelty Suppressed Feeding Test (NSFT) assays remained consistent, such that the model reliably produced depression-like behaviors in animals as elucidated in these assessments [37,53,56,63,66,67,73].…”

Section: Reserpine Evaluationmentioning

confidence: 98%

“…Additional data for depression-like behaviors were identified with the Tail Suspension Test (TST) paradigm [49,51,58,66], although results failing to find these effects were also highlighted [72]. Results from Sucrose Preference Test (SPT) and Novelty Suppressed Feeding Test (NSFT) assays remained consistent, such that the model reliably produced depression-like behaviors in animals as elucidated in these assessments [37,53,56,63,66,67,73]. Further investigation into depression-like behavior using the splash test yielded mixed results, with one study reporting reduced grooming behaviors [56], while others did not [53,64].…”

Section: Reserpine Evaluationmentioning

confidence: 99%

“…In assessments where FST was the sole measure of affect, the following treatments were reported as effective in alleviating behavioral despair associated with the reserpine model of FMS: curcumin [38], Phα1β [39], laser irradiation [41], duloxetine or a duloxetine-gamma irradiation combination treatment [41], imipramine [43], I2R agonists [43], combination treatment with folic acid and melatonin [44], B1R receptor KO or selective antagonists [45], and Cur-IONPs [46]. In other affective measures of FMSlike pain, evidence has been provided for improvement with a variety of antidepressants, including imipramine [49,54,56], duloxetine [37], desvenlafaxine [37], amitryptiline [59], citalopram [66], vortioxetine [75], and fluoxetine [61,62]. Evidence has also been provided for anticonvulsants gabapentin [61] and analog pregabalin [58].…”

Section: Reserpine Evaluationmentioning

confidence: 99%

“…Additionally, changes to diet and exercise have been shown to alleviate negative emotionality associated with this model [53,72]. Further alternative approaches have been identified for improving affect in animals as well, including ferulic acid [49], resveratrol [52], tactile stimulation [56], fisetin [58], melatonin [22,77], CoQ10 [60], Yukmijihwang-won [61], carotenoids [85], electroacupuncture [22,79], and thymoquinone [66]. Drugs that promote neuro-recovery, such a cerebrolysin [61], and neuroprotection, such as TIQ and 1MeTIQ [50], provide further promise.…”

Section: Reserpine Evaluationmentioning

confidence: 99%

See 2 more Smart Citations

The Fibromyalgia Pain Experience: A Scoping Review of the Preclinical Evidence for Replication and Treatment of the Affective and Cognitive Pain Dimensions

Argenbright,

Bertlesman,

Russell

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Fibromyalgia is a chronic, widespread pain disorder that is strongly represented across the affective and cognitive dimensions of pain, given that the underlying pathophysiology of the disorder is yet to be identified. These affective and cognitive deficits are crucial to understanding and treating the fibromyalgia pain experience as a whole but replicating this multidimensionality on a preclinical level is challenging. To understand the underlying mechanisms, animal models are used. In this scoping review, we evaluate the current primary animal models of fibromyalgia regarding their translational relevance within the affective and cognitive pain realms, as well as summarize treatments that have been identified preclinically for attenuating these deficits.

show abstract

Stem cells therapeutic effect in a reserpine-induced fibromyalgia rat model: A possible NLRP3 inflammasome modulation with neurogenesis promotion in the cerebral cortex

et al. 2023

View full text Add to dashboard Cite

Effects of thymoquinone in a rat model of reserpine-induced depression

Cited by 4 publications

References 37 publications

Reserpine-induced rat model of depression: behavioral, physiological and dopamine receptor PET based validation

Reserpine-induced rat model of depression: behavioral, physiological and dopamine receptor PET based validation

The Fibromyalgia Pain Experience: A Scoping Review of the Preclinical Evidence for Replication and Treatment of the Affective and Cognitive Pain Dimensions

Stem cells therapeutic effect in a reserpine-induced fibromyalgia rat model: A possible NLRP3 inflammasome modulation with neurogenesis promotion in the cerebral cortex

Contact Info

Product

Resources

About